Issue 37 - The Cancer Letter

Request Cancellation

Subscription Change

This change will be effective immediately and your card will be charged a prorated amount based on your existing subscription level.

OK Cancel

Renew today!

Your subscription has lapsed. Subscribe today to access this content.

SUBSCRIBE NOW

Subscriber content

Log in or subscribe to access The Cancer Letter.

LOGIN SUBSCRIBE NOW

SEARCH DATE

SEARCH TEXT

Cancel

OK

Cancel

OK

Delete Account

Are you sure you want to delete your account? This will erase all of your account data from the site. To delete your account enter your password below

Former American Cancer Society CEO John Seffrin endorses cancer research venture funded by Philip Morris

How PR firms created “dialogue” structure used by cancer groups and tobacco clients

Matt Myers: Philip Morris has a long history of funding what it calls independent research by previously credible researchers

Allan Erickson: “I think Philip Morris has a long-term goal of a smoke-free world

The Write Treatment; when a writing workshop is a part of cancer treatment

In Brief

Sunil Sharma joins TGen, City of Hope and HonorHealth

Wisconsin state budget expands precision medicine in cancer

Drugs & Targets

FDA approves sNDA for Alunbrig tablets, Takeda announces

FDA grants priority review for Genentech's Perjeta in adjuvant HER2+ early breast cancer

Mylan launches generic Gleevec tablets

Amgen, CytomX Therapeutics form immuno-oncology collaboration

Recent Issues

Renew today!

Subscriber content

Never miss an issue!

Login